This is important regarding that such mutants disable therapy with the FLT3-specific TKi quizartinib (vulnerable to D835 substitutions [53]) and the broad-range TKi midostaurin (vulnerable to N676K [54]), which is FDA-approved for FLT3-mutant AML [16,17]. The gene discussed is FLT3; the disease is acute myeloid leukemia.